ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
0,00%
Bitcoin
66.089,85
-0,15%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) News

SNGX Soligenix Inc

4,06
-0,09 (-2,17%)
15 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Soligenix Inc SNGX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,09 -2,17% 4,06 06:00:11
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,05 3,84 4,78 4,06 4,15
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.6.202413:30PRNUSA Comparison of Vaccine Technologies to be Presented at the..
05.6.202414:00GLOBESetting the Stage for Success: PRISM MarketView Highlights..
31.5.202414:00EDGAR2Form 8-K - Current report
31.5.202413:30PRNUSSoligenix Announces Reverse Stock Split
29.5.202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29.5.202413:30PRNUSSoligenix Encourages Stockholders to Vote their Shares at..
28.5.202422:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24.5.202422:05EDGAR2Form 8-K - Current report
24.5.202413:30PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
23.5.202413:30PRNUSSoligenix Encourages Stockholders to Vote "FOR" Reverse..
22.5.202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21.5.202418:35GLOBEPRISM MarketView Highlights Soligenix, Inc. as it Builds on..
21.5.202413:30PRNUSSuVax™ and MarVax™ Thermostable Vaccine Platform to be..
20.5.202413:30PRNUSSoligenix Encourages Stockholders to Vote Prior to Annual..
17.5.202422:25EDGAR2Form 8-K - Current report
17.5.202422:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16.5.202413:30PRNUSPositive Clinical Results from HyBryte™ Compatibility Study..
15.5.202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10.5.202422:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10.5.202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.5.202413:30PRNUSSoligenix Announces Recent Accomplishments And First Quarter..
06.5.202413:30PRNUSSoligenix to Present at Upcoming Conferences
25.4.202413:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18.4.202414:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15.4.202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11.4.202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03.4.202413:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15.3.202412:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08.2.202413:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25.1.202413:30PRNUSSoligenix to Present at The Microcap Conference
08.1.202413:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04.1.202413:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02.1.202413:30PRNUSSoligenix Announces Publication Demonstrating Complete..
22.12.202322:05EDGAR2Form 8-K - Current report
18.12.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15.12.202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202322:03EDGAR2Form 8-K - Current report
08.12.202323:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.12.202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.12.202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.12.202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.12.202322:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01.12.202313:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30.11.202313:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
17.11.202322:05EDGAR2Form 8-K - Current report
17.11.202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
13.11.202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
SNGX
Soligenix
TG
A3K2LY
Commonwealth Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten